The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Open accessAbstract
Neurotoxic amyloid beta peptide (Abeta) accumulates in the brains of individuals with Alzheimer disease (AD). The APOE4 allele is a major risk factor for sporadic AD and has been associated with increased brain parenchymal and vascular amyloid burden. How apoE isoforms influence Abeta accumulation in the brain has, however, remained unclear. Here, we have shown that apoE disrupts Abeta clearance across the mouse blood-brain barrier (BBB) in an isoform-specific manner (specifically, apoE4 had a greater disruptive effect than either apoE3 or apoE2). Abeta binding to apoE4 redirected the rapid clearance of free Abeta40/42 from the LDL receptor-related protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalized apoE4 and Abeta-apoE4 complexes at the BBB more slowly than LRP1. In contrast, apoE2 and apoE3 as well as Abeta-apoE2 and Abeta-apoE3 complexes were cleared at the BBB via both VLDLR and LRP1 at a substantially faster rate than Abeta-apoE4 complexes. Astrocyte-secreted lipo-apoE2, lipo-apoE3, and lipo-apoE4 as well as their complexes with Abeta were cleared at the BBB by mechanisms similar to those of their respective lipid-poor isoforms but at 2- to 3-fold slower rates. Thus, apoE isoforms differentially regulate Abeta clearance from the brain, and this might contribute to the effects of APOE genotype on the disease process in both individuals with AD and animal models of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using homozygous human APOE knock-in mice, previous work demonstrated that APOE4 promotes A β aggregation and impairs its clearance relative to APOE3 34,38,39 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE exerts toxic effects on the cerebrovascular system (694) and neurons (383, 384) and influences A 𝛃 clearance (60, 64, 98, 135, 256, 266, 278, 294, 315, 693), amyloid deposition (39, 256, 258, 266, 278, 314, 518, 612), and tau-related neurodegeneration (533) in an allele-dependent manner APOE4 > APOE3 > APOE2 .”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact increased rate of soluble Aβ clearance across the BBB has been experimentally confirmed in the setting of the APOE ε2 allele [32, 48].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, the contribution of ISF bulk flow to total Aβ clearance was minimal (Fig. 1B), consistent with previous studies (14, 15, 20).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When injecting low nM [ 125 I] Aβ 1-42 concentrations in mice, we found no significant amount of radioactivity in the CSF, showing that the small amounts of injected Aβ are rapidly cleared via the BBB and that a minor amount of injected Aβ is cleared via bulk flow as also observed by previous studies (8,11,12).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12,35), LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations.”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, with an endocytosis rate up to 16 times faster than that of other Aβ receptors, such as VDLDR or LDLR (12,35), LRP1 may outperform other receptors in Aβ clearance, especially at higher concentrations.”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LRP1 also binds APOE2 and APOE3 as well as APOE2-A 𝛃 and APOE3-A 𝛃 complexes at the abluminal side of the BBB, mediating their efflux from brain-toblood (135).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“Studies in animal models support that APOE4 compared with APOE3 and APOE2 diminishes A 𝛃 clearance across the BBB (58, 135), which has been confirmed in transgenic APOE4 mice (98).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“and in animal models, APOE4 compared with APOE3 and APOE2 leads to impaired clearance of A 𝛃 across the BBB (58, 98, 135) and an early BBB breakdown and transporters' dysregulation (9, 60, 85, 437).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [135]
The cited source says what the claim attributes to it.
In the citing paper
“A recent study wherein apoE/Aβ complexes were microinjected into wildtype mouse brain revealed that Aβ bound to apoE4 is cleared more slowly than when Aβ is complexed to apoE3 or apoE2 (56).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [56]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies demonstrated that apoE isoforms can differentially affect Aβ clearance (Deane et al., 2008; Jiang et al., 2008; Castellano et al., 2011).”
From Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, recent studies strongly suggest that apoE regulates both extracellular and intracellular Aβ clearance in the brain (Bell et al., 2007; Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, apoE has been shown to regulate Aβ clearance in the brain (Bell et al., 2007; Deane et al., 2008; DeMattos et al., 2004; Jiang et al., 2008).”
From Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Aβ complexed to apoE2 and apoE3 is cleared out of the brain at a significantly faster rate than Aβ complexed to apoE4 (Deane et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“A recent study has shown that the brain to blood clearance of lipidated apoE4 in the mouse brain is significantly lower than the clearance of apoE3 and apoE2 (Deane et al., 2008).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Accumulating recent evidence strongly suggests that when human apoE is complexed with Aβ, the brain to blood clearance of Aβ is actually decreased compared to that of free Aβ (Bell et al., 2007; Deane et al., 2008; Ito et al., 2007).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Deane et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“In animal models, Aβ–ApoE2 and Aβ–ApoE3 complexes are cleared by the blood brain barrier (BBB) at a substantially higher rate than Aβ–ApoE4 complexes [23].”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“These results suggest the LDLR overexpression in neurons and astrocytes (18) likely increases BBB-mediated Aβ clearance through an indirect mechanism involving other apoE receptors at the BBB, such as LRP1—a receptor shown to directly mediate Aβ clearance across the BBB (14, 15, 26).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“our work strongly suggests that LDLR influences Aβ metabolism by affecting its clearance from the brain into blood, a mechanism previously suggested only for LRP1 and VLDLR (13–15, 26).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Although low-density lipoprotein receptor-related protein 1 (LRP1) has been well characterized for its role in BBB-mediated Aβ clearance (13–15), whether LDLR plays a role in Aβ clearance across the BBB is unclear.”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“ApoE has been shown to impede the clearance of Aβ from brain ISF (13, 15, 43); therefore, it is likely that the reduction of apoE levels with LDLR overexpression facilitates greater ISF Aβ clearance across the BBB.”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies suggest that transport across the BBB is a major elimination route for brain Aβ (8,11,12,15).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, levels of apoE in human cerebrospinal fluid do display genotype-dependent pattern similar to the pattern in plasma, further murine interstitial fluid was observed to have genotype-dependent apoE levels similar to the pattern in cerebrospinal fluid [105,112,113].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [113]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, levels of apoE in human cerebrospinal fluid do display genotype-dependent pattern similar to the pattern in plasma, further murine interstitial fluid was observed to have genotype-dependent apoE levels similar to the pattern in cerebrospinal fluid [105,112,113].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [113]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular regulation in the normal brain and in Alzheimer's disease
Iadecola, C. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1387 · Cited by 2,213
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“Clearance of Alzheimer’s amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
BackgroundA68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1×
“Clearance of Alzheimer’s amyloid β(1-40)-peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.”
BackgroundShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationRovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Research works printed but not linked: 2
- Tanzi, 2004, Neuron., 43, 605
- 10.1042/0264-6021:3480359 · DOI · Paper page
Cited by
Sorted by citations
Items 601–700 of 767
Pearson, A. G., Miller, K. B., Corkery, A. T., Loggie, N. A., Howery, A. J., Rivera‐Rivera, L. A., Wieben, O. E., Johnson, K. M., Johnson, S. C., & Barnes, J. N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314744 · Cited by 5
Bamel, K., Panwar, A., Kumar, M., Kumar, S., Sharma, V., & Sharma, A. K. (2025) · Brain Disorders · doi:10.1016/j.dscb.2025.100232 · Cited by 5
The Janus face of CaMKII: from memory consolidation to neurotoxic switch in Alzheimer’s disease
Tang, L., Liu, F., Sun, X., Yang, J., Liu, Y., Pan, X., Hao, L., Lou, F., & Su, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04160-7 · Cited by 5
Elshazly, A. M., Sinanian, M. M., Elimam, D. M., & Zakaria, S. (2023) · Neuroglia · doi:10.3390/neuroglia4030014 · Cited by 5
A Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta
Zhang, H., Xu, Q. F., Zhao, Y., He, N., Ren, Z., Xiang, Q., Tang, Z., & Liu, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673269288231123095215 · Cited by 5
Nguchu, B. A., Han, Y., Wang, Y., & Shaw, P. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1453852 · Cited by 5
Schofield, C. L., Rodrigo‐Navarro, A., Dalby, M. J., Agtmael, T. V., & Salmerón‐Sánchez, M. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000068 · Cited by 5
Silencing of Amyloid Precursor Protein Expression Using a New Engineered Delta Ribozyme
Aissa, M. B., April, M.-C., Bergeron, L. J., Perreault, J., & Lévesque, G. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/947147 · Cited by 5
Genetic Variants and Related Biomarkers in Sporadic Alzheimer’s Disease
Guerreiro, R. J., Brás, J., Toombs, J., Heslegrave, A., Hardy, J., & Zetterberg, H. (2014) · Current Genetic Medicine Reports · doi:10.1007/s40142-014-0062-6 · Cited by 6
Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer’s disease
Paranjpe, M. D., Chaffin, M. D., Zahid, S., Ritchie, S. C., Rotter, J. I., Rich, S. S., Gerszten, R. E., Guo, X., Heckbert, S. R., Tracy, R., et al. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010294 · Cited by 5
Zhou, S., & Sun, X. (2012) · PubMed · Cited by 5
Pająk, B., Kania, E., Gołaszewska, A., & Orzechowski, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061481 · Cited by 5
Design and characterization of a novel dimeric blood–brain barrier penetrating TNFα inhibitor
Suárez, V. M., Macaya, L., Contreras, M. A., Parra, N. C., Maura, R., González, A., Toledo, J. R., & Sánchez, O. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26173 · Cited by 6
The role of inflammation in neurodegenerative diseases
Appel, S. H., Beers, D. R., & Zhao, W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00036-8 · Cited by 5
Erickson, M. A., Nicolazzo, J. A., & Banks, W. A. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.08.016 · Cited by 5
Kreutzer, E., Short, J. L., & Nicolazzo, J. A. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03731-0 · Cited by 4
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 5
Huang, S., Nunez, J., Toresco, D. L., Wen, C., Slotabec, L. A., Wang, H., Zhang, H., Rouhi, N., Adenawoola, M. I., & Li, J. (2025) · The FASEB Journal · doi:10.1096/fj.202402725rr · Cited by 4
Transport pathways across the blood-brain barrier for waste clearance and drug delivery
Gröbner, L. S., & Pietrzik, C. U. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00812-7 · Cited by 4
Maladie d’Alzheimer et anesthésie : relations potentielles et implications cliniques
André, D., Dartigues, J.-F., & Sztark, F. (2010) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2010.10.013 · Cited by 4
Park, D. C., & Farrell, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411469-2.00005-4 · Cited by 4
Role of Inflammation in Neurodegenerative Diseases
Appel, S. H., Beers, D. R., & Zhao, W. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00025-2 · Cited by 4
Modulating Role of TTR in Aβ Toxicity, from Health to Disease
Cardoso, I., Santos, L. M., & Alemi, M. (2016) · InTech eBooks · doi:10.5772/63194 · Cited by 7
Kim, D., Gim, J., Mishra, A., Lee, K., Cho, Y., & Kim, H. (2017) · Genes & Genomics · doi:10.1007/s13258-017-0524-9 · Cited by 4
The Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
Serrano, E., Sanz, P. G., & Barrantes, F. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_29 · Cited by 4
Glymphatics, Cranium, and the Brain Homeostasis
Zibitt, M., Makhoul, V., Yu, J. C.-K., Nguyen, K. D., & Williams, J. K. (2023) · FACE · doi:10.1177/27325016231160291 · Cited by 6
Genspezifische Therapieansätze bei der Alzheimer-Krankheit und anderen Tauopathien
Feneberg, E., & Otto, M. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-00872-6 · Cited by 4
Emerging Therapeutic Strategies in Alzheimer's Disease
Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5
Lipids and Lipoproteins in Alzheimer’s Disease
Stukas, S. K., Kulić, I., Zareyan, S., & Wellington, C. L. (2015) · InTech eBooks · doi:10.5772/59808 · Cited by 5
Apolipoprotein E and Alzheimer's disease pathology in a diverse autopsy study
Suemoto, C. K., Paradela, R. S., Leite, R. E. P., Paes, V. R., Pasqualucci, C. A., Ferriolli, E., Zatz, M., Santos, G. D. N., de Alexandria, M. A. L. S., Pereira, A. C., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70927 · Cited by 3
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
Hartmann, C., Haferkamp, U., Appelt‐Menzel, A., Barenberg, J., Brachner, A., Ehrhard, T., Feldhaus, J. S., Gerhartl, A., Hollemann, T., Kulka, L. A. M., et al. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00753-7 · Cited by 4
Amyloid-β clearance: an astrocytic perspective
Li, J., Lv, Z., Chen, X. P., Fu, F., Yang, K., Lai, G., Wu, H., & Xie, G. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1812081 · Cited by 3
Daneshpour, A., Nasiri, H., Motamed, A. K., Heidarzadeh, N., Fard, A. M., Koleini, S., Fakhimi, F., Abiri, L., Mayeli, M., Sadeghi, M., et al. (2025) · Neurological Sciences · doi:10.1007/s10072-025-07992-4 · Cited by 3
Yu, Z., Liu, X., Li, Q., Tuo, J., Tan, Q., Liu, Z., Yuan, Z., Zeng, R., Zhao, Y., Li, J., et al. (2025) · Aging Cell · doi:10.1111/acel.70205 · Cited by 3
TaqTth-hpRNA: a novel compact RNA-targeting tool for specific silencing of pathogenic mRNA
Xu, C., Cao, J., Qiang, H., Liu, Y., Wu, J., Luo, Q., Wan, M., Wang, Y., Wang, P., Qian, C., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03326-3 · Cited by 3
Targeting low-density lipoprotein receptors with protein-only nanoparticles
Xu, Z., Céspedes, M. V., Unzueta, U., Álamo, P., Pesarrodona, M., Mangues, R., Vázquez, E., Villaverde, A., & Ferrer‐Miralles, N. (2015) · Journal of Nanoparticle Research · doi:10.1007/s11051-015-2959-8 · Cited by 3
Apolipoprotein E polymorphism carriers exhibit objective cognitive deficits: a single center trial
Zeng, Y., Huang, X., Elkin, K. B., Stone, C., Rajah, G. B., Guan, L., Du, H., & Geng, X. (2020) · Neurological Research · doi:10.1080/01616412.2020.1782130 · Cited by 3
Cognition in Patients With Memory Difficulties and Dementia Relative to APOE e4 Status
Hestad, K. A., Engedal, K., Horndalsveen, P. O., & Strand, B. H. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.686036 · Cited by 3
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Improving mouse models for the study of Alzheimer's disease
Reagan, A. M., Onos, K. D., Heuer, S. E., Sasner, M., & Howell, G. R. (2022) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2021.12.005 · Cited by 5
The ABCA7 transporter, brain lipids and Alzheimer’s disease
Soscia, S. J., & Fitzgerald, M. L. (2013) · Clinical Lipidology · doi:10.2217/clp.12.91 · Cited by 3
Diet and Nutrition in Alzheimer’s Disease and Healthy Aging
Sharma, P., Gaur, V. K., & Srivastava, J. K. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_10 · Cited by 3
Robert, J., Cheng, W. H., Hayat, A., Ward-Able, T., & Wellington, C. L. (2015) · Clinical Lipidology · doi:10.2217/clp.14.64 · Cited by 3
Jasmin, S. B. (2011) · eScholarship@McGill (McGill) · doi:10.82308/52384 · Cited by 3
Arnaud, K., Moreira, V. O., Vincent, J. D., Dallérac, G. M., Poupon, C. L., Richter, M., Müller, U., Rondi‐Reig, L., Prochiantz, A., & Nardo, A. A. D. (2019) · HAL · Cited by 3
Das, G., & Milner, T. E. (2024) · Frontiers in Photonics · doi:10.3389/fphot.2024.1389683 · Cited by 2
Iacono, D. (2025) · Neuroethics · doi:10.1007/s12152-025-09624-2 · Cited by 2
A circadian clock regulates the blood-brain barrier across phylogeny
Avila, A., & Zhang, S. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.04.004 · Cited by 2
Wen, P., Han, C., Zhao, H., Yao, S., & Chen, H. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251384245 · Cited by 2
Lipid metabolism in the central nervous system and neurodegenerative diseases
Hayashi, H. (2011) · Folia Pharmacologica Japonica · doi:10.1254/fpj.137.227 · Cited by 2
Biomarkers of Alzheimer’s disease
Pitt, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-404630-6.00048-8 · Cited by 2
Gao, Y., Li, X., Liu, X., Zhao, Q., Che, X., Guo, Q., Ren, R., & Wang, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.51 · Cited by 2
Chi, C.-H., Chiu, Y., & Chang, Y. (2019) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acz047 · Cited by 2
Neuroprotective Effects of Extra‐Virgin Olive Oil and its Components in Alzheimer's Disease
Abuznait, A. H., Qosa, H., Mohamed, L. A., Batarseh, Y. S., & Kaddoumi, A. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch14 · Cited by 2
Benmimoun, B., Papastefanaki, F., Périchon, B., Segklia, K., Roby, N., Miriagou, V., Schmitt, C., Dramsi, S., Matsas, R., & Spéder, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.28.970376 · Cited by 2
Chen, M., Kretzschmar, D., Verdile, G., & Lardelli, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00025-7 · Cited by 2
Network mechanism analysis between hippocampal development and Alzheimer's disease
Xu, S., Liu, Z.-T., Yang, X.-Y., Huang-Fu, X., Yue, B., & Tang, X.-H. (2025) · New medicine. · doi:10.61958/nmfu1373 · Cited by 1
Abasi, M., Kianmehr, A., Variji, A., Sangali, P., & Mahrooz, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.04.012 · Cited by 1
Skull base foramina provide a route for the exit of brain lymphatic vessels from the human skull
Altınöz, D., Rahimova, Z., Gürses, İ. A., Kurtoğlu, F., & Çavdar, S. (2025) · Surgical and Radiologic Anatomy · doi:10.1007/s00276-025-03796-5 · Cited by 1
Arzola, E. P., Yu, G., Xiong, L., Lee, D., Wu, A., Paruchuri, S., Skinner, J., Wang, M., Zhang, B., Mei, L., et al. (2025) · Glia · doi:10.1002/glia.70114 · Cited by 1
Treatment options for Alzheimer’s Disease: An overview of the amyloid, tau, and alternate hypotheses
Eroltu, K. (2023) · Journal of High School Science · doi:10.64336/001c.89250 · Cited by 1
Leckey, C. A., Giovannucci, T. A., Murphy, E. C., Moncur, E. M., Tariq, K., Aslanyan, A., Schöll, M., Srikrishna, M., Coath, W., Barker, S., et al. (2026) · Brain Communications · doi:10.1093/braincomms/fcag029 · Cited by 1
Sambhariya, W. S., Rickman, C. B., D'Amore, P. A., Corradetti, G., Hageman, G. S., Howell, G. R., Marola, O. J., Phatnani, H. P., Philp, N. J., Sinha, D., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101449 · Cited by 1
Protective mutations associated with APOE in Alzheimer’s disease
Ma, Y., Li, Y., Wu, G., Liu, L., Tian, M., Han, X., Chen, X., Xuan, X., Zheng, T., Gao, X., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03496-5 · Cited by 1
Modeling diseases of aging in larval zebrafish, a paradoxical yet powerful strategy
Özcan, G. G., & Rihel, J. (2026) · Genetics · doi:10.1093/genetics/iyag027 · Cited by 1
Stimmell, A. C., Alday, L. J., Salvador, E. M., Diaz, J. M., Moseley, S. C., Cushing, S. D., Zheng, Y., Ogg, J. D., Ragsdale, S. M., & Wilber, A. A. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261429996 · Cited by 1
Saravanan, J., Easwaran, V., Selvaraj, D., Gunasekaran, V., Soumya, V., Thiruselvi, M., Prasanth, M. L., Singh, S., Ellaiyarasu, C., Rai, P. K., et al. (2026) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2026.104108 · Cited by 1
Ti, K., Zhao, Y., Tan, E., & Ma, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146254 · Cited by 1
Herpes simplex virus infection and Alzheimer’s disease
Hur, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1858017 · Cited by 1
Multiple Sclerosis, Alzheimer’s Disease, and Inflammation: A Hypothetical View
Bynoe, M. S., & Viret, C. (2012) · Molecular and integrative toxicology · doi:10.1007/978-1-61779-812-2_9 · Cited by 1
Revisiting the genetics of APOE
Carmona, S., Kun‐Rodrigues, C., Brás, J., & Guerreiro, R. J. (2017) · UCL Discovery (University College London) · Cited by 1
Altered RNA Metabolism in Neurodegenerative Disorders
Chimata, A. V., Deshpande, P., & Singh, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4288-2_9 · Cited by 1
Littleford, K., Tyler, L., Dashwood, M., Reed, H., & Kuruvilla, T. (2024) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.12008 · Cited by 1
Lipoproteins and Apolipoproteins in Alzheimer's Disease
Matsubara, E. (2012) · InTech eBooks · doi:10.5772/45977 · Cited by 1
Catabolism and Anabolism of Amyloid-β
Hashimoto, S., Nilsson, P., & Saido, T. C. (2015) · Springer eBooks · doi:10.1007/978-4-431-55763-0_19 · Cited by 2
New Data on Risk Gene for Alzheimer Disease Suggests Different Therapeutic Targets
Valeo, T. (2011) · Neurology Today · doi:10.1097/01.nt.0000403763.91117.f3 · Cited by 1
Perez‐Lloret, S., Bernath, V., & Barrantes, F. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-95360-1_29 · Cited by 1
Amyloid-β in Brain Aging and Alzheimer’s Disease
Sasaguri, H., & Saido, T. C. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_21 · Cited by 1
Yeast as a Model for Studying Aβ Aggregation, Toxicity and Clearance
Bharadwaj, P. (2011) · Australasian Journal of Paramedicine · Cited by 1
Menon, C. V. (2014) · ThinkTech (Texas Tech University) · Cited by 1
(2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832cef8f · Cited by 1
APOE Impacts Lipid Trafficking in Retinal Pigment Epithelium CellsPreprint
Richards, S. E. V., Demirs, J. T., Jose, S., Fan, L., Xu, Y., Esterberg, R., Huang, C. L., Wilson, C. W., Saint‐Geniez, M., & Liao, S.-M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.30.596647 · Cited by 1
Chen, K., Chen, Y., Ren, Y., Wang, Z., Huang, Y., Pan, M., Li, Z., Casey, M. C., Qiao, W., Shi, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78407-x
Self-citationTargeting Early Stages of Alzheimer’s Disease in a Transgenic Model
Lord, A. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Simmons, C. R. (2011) · UKnowledge (University of Kentucky)
Role of the 39-kDa receptor-associated protein (RAP) in Alzheimer's disease
Hoang, T. (2012) · UTAS Research Repository · doi:10.25959/23206328
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
Abad‐Rodríguez, J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.002
P2‐030: INVESTIGATING THE ROLE OF CLU, PICALM, AND CR1 IN ALZHEIMER'S DISEASE
Lord, J., Turton, J. C., Braae, A., Barber, I., Medway, C., Brown, K. S., & Morgan, K. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.703
Merlin, J. L. P. (2013) · Journal of the Chosun Natural Science · doi:10.13160/ricns.2013.6.3.125
Brain Effect Site Pharmacokinetics: Delivery of Biologics Across the Blood–Brain Barrier
Fricker, G., & Mahringer, A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse552
COMPUTERIZED TOOLS: A SUBSTITUTE OR A SUPPLEMENT WHEN DIAGNOSING ALZHEIMER'S DISEASE?
Palomeque, A., & Alberto, C. (2015) · Figshare
Adipokines and Alzheimer's Disease
Sortino, M. A., Merlo, S., & Spampinato, S. F. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733434-00130
Aronsen, E. (2009) · Duo Research Archive (University of Oslo)
Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Self-citationAlbrecht, M. A., & Foster, J. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_7
Munger, E. L. (2016) · OhioLink ETD Center (Ohio Library and Information Network)
Metadata
- Authors
- Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V.
- Affiliations
- University of Rochester Medicine (US)
- Washington University in St. Louis (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2008-12-01
- Volume
- 118
- Issue
- 12
- Pages
- 4002-4013
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC2582453
- OpenAlex
- W2138992210
- Cited by
- 771
- References
- 71
- Citations by year
- 2026: 35 · 2025: 39 · 2024: 51 · 2023: 40 · 2022: 42 · 2021: 48 · 2020: 47 · 2019: 47 · 2018: 35 · 2017: 49 · 2016: 38 · 2015: 51 · 2014: 48 · 2013: 41 · 2012: 52
- FWCI
- 24.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- National Institutes of Health (R37 NS34467, NS34467, AG13956, R37 AG13956)
- National Institute on Aging (R37AG023084, R37AG13956, R37AG013956)
- National Institute of Neurological Disorders and Stroke (R37NS034467, R37NS34467)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- APOE isoforms, APOE ε4, Alzheimer's disease, blood-brain barrier, LRP1, VLDLR, APOE2, APOE3, amyloid accumulation
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Blood-Brain Barrier, Disease Models, Animal, Humans, Male, Receptors, LDL, Amyloid beta-Peptides, Protein Isoforms, Tumor Suppressor Proteins, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Apolipoprotein E3, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
